CMO

New Research Reveals Influencers Significantly Drive Purchasing Decisions

Retrieved on: 
Thursday, April 25, 2024
Internet celebrity, CMO, Social media, Internet, AI, Sport, Research, Gen, Generation Z, Food, Athlete, Beauty

CHICAGO, April 25, 2024 (GLOBE NEWSWIRE) -- Influencers have cemented themselves as key components of modern marketing strategies, and new research reveals the significant power they have in directly shaping consumer purchasing behaviors.

Key Points: 
  • CHICAGO, April 25, 2024 (GLOBE NEWSWIRE) -- Influencers have cemented themselves as key components of modern marketing strategies, and new research reveals the significant power they have in directly shaping consumer purchasing behaviors.
  • Gen Z consumers reportedly trust influencers at a higher rate and are more likely to make daily or weekly purchases compared to other consumers.
  • “Our research makes it clear that influencers are not only viable but necessary partners to tap into consumer trust, especially among younger generations.
  • Consumer attitudes toward AI influencers: The rise of generative AI has led to the birth of AI-generated influencers.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder, and Perion and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 25, 2024
FDA, Radiation, CMO, Sonder, ChatGPT, News, Risk, Food, Annual report, Complaint, Biologics license application, P.C, Microsoft, Patient, Acquisition, CKPT, BLA, Bank statement, CRL, Growth

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • For more information on the Sonder class action go to: https://bespc.com/cases/SOND
    Perion’s most significant search partner and largest source of revenue is Microsoft.
  • For more information on the Perion class action go to: https://bespc.com/cases/PERI

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
Thursday, April 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, April 24, 2024
PFS, CMO, AMF, Cash, Pancreatic cancer, Research, Webcast, Lung, RT, AACR, Lung cancer, EIB, Conference call, Annual report, NBTXR3, ESMO, Conference, Janssen, NSCLC, Monroe Dunaway Anderson, Survival, Johnson & Johnson, Research and development, OS, Therapy, Neoplasm, Clinical trial, Cancer, Esophageal cancer, Immunotherapy, MD, Administration, University, URD, Patient, NANO, MD Anderson Cancer Center, Head, Bank statement, Growth, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2023 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • “2023 was an incredible year of progress for Nanobiotix and our NBTXR3 program.
  • “During 2023, we reported prolonged survival from Study 102 in head and neck cancer further reinforcing the design of our ongoing pivotal NANORAY-312 trial.
  • Cash and Cash Equivalents: As of December 31, 2023, Nanobiotix had €75.3 million in cash and cash equivalents, compared to €41.4 million as of December 31, 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Retrieved on: 
Wednesday, April 24, 2024
FDA, Radiation, Action Replay, CMO, LLP, Person, Prior, News, Food, Complaint, Pomerantz, Biologics license application, District court, Patient, Court, Ext, Acquisition, CKPT, BLA, Checkpoint

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.

Key Points: 
  • NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer

Retrieved on: 
Wednesday, April 24, 2024
University, CMO, Safety, NDA, Skin, Leo Pharma, Dermatology, Doctor of Philosophy, Freedom, Engineering, Patient, Doctor of Pharmacy, Secukinumab, Psoriasis, Therapy, Celgene, Biotechnology, Chronic kidney disease, Pharmaceutical industry

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the strengthening of its leadership team with the addition of two experienced executives.

Key Points: 
  • Joana Goncalves, MBChB, will serve as Oruka’s Chief Medical Officer, effective April 18, 2024.
  • Dr. Goncalves brings two decades of leadership experience in dermatology clinical development and medical affairs.
  • Oruka also announced that Eugenia Levi, PharmD, will join the company as Vice President of Medical Affairs.
  • Her extensive leadership experience will prove invaluable as we advance our portfolio of potentially best-in-class antibodies and build a high-performing team,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics.

InfiniBox™ SSA II Named One of the Top 5 Cyber Secure High-End All-Flash Arrays for Enterprise Storage by Storage Analyst Firm DCIG

Retrieved on: 
Wednesday, April 24, 2024
CMO, SSA, Machine learning, Research, Artificial intelligence, CAPEX, AFA, Asatru Folk Assembly, Infinidat, Multiverse, OPEX, Computer data storage

WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Infinidat , a leading provider of enterprise storage solutions, today announced that the InfiniBox™ SSA II is recognized by the analyst firm DCIG as one of the world’s top cyber secure all-flash arrays (AFA) for enterprise storage.

Key Points: 
  • WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Infinidat , a leading provider of enterprise storage solutions, today announced that the InfiniBox™ SSA II is recognized by the analyst firm DCIG as one of the world’s top cyber secure all-flash arrays (AFA) for enterprise storage.
  • “The 2024-25 DCIG Top 5 Cyber Secure High-End All Flash Arrays Report” is now available.
  • “Ever since we delivered the groundbreaking capabilities of InfiniBox SSA with our InfiniSafe cyber storage software and our InfiniVerse platform, Infinidat has redefined cyber resilience and recovery for enterprise storage.
  • Our list of the Top 5 Cyber Secure High-End All Flash Arrays constitutes the future of enterprise storage.

AMA New York Announces Inductees to 2024 Marketing Hall of Fame

Retrieved on: 
Tuesday, April 23, 2024
Lazarus, CMO, Catalysis, P&G, Ad Age, Purpose, Hall, Burger King, Coca-Cola, Modulo, Communications officer, Dentsu International, Mastercard, NotCo, Netflix, Wind, Name, Marketing Hall of Fame, Visa, Ogilvy (agency), Baruch College, American Express, Activision Blizzard, Marketing, UM, MetLife, Burrell Communications Group, Delta Air Lines, Greenbook, Accenture, IBM, Film industry

NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- The American Marketing Association New York today announced the names of the extraordinary business and marketing leaders who will be inducted into the Marketing Hall of Fame® in 2024.

Key Points: 
  • NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- The American Marketing Association New York today announced the names of the extraordinary business and marketing leaders who will be inducted into the Marketing Hall of Fame® in 2024.
  • “Marketing Hall of Fame has celebrated innovation and impact in marketing for 11 years,” commented AMA New York President Lori Johnson.
  • Established by the AMA New York, the Marketing Hall of Fame is the only distinction that rewards excellence in marketing across all sectors.
  • The 2024 Marketing Hall of Fame inductees personify the talent and drive behind great marketing, and their creative brilliance continues to push boundaries and captivate audiences.

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Retrieved on: 
Tuesday, April 23, 2024
Ulcerative colitis, CMO, Science, Strand Life Sciences, Machine learning, Partnership, PDE4, Therapy, Data, Patient, Biomarker, Medicine, Autoimmunity, UC

Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

Key Points: 
  • The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
  • "Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment," said Dr. Mitch Jones, CMO at Palisade Bio.
  • "We are thrilled to collaborate with Palisade Bio in this transformative endeavor toward advancing precision medicine for ulcerative colitis therapy," added Ramesh Hariharan, CEO at Strand Life Sciences.
  • Palisade Bio is committed to advancing precision medicine solutions for UC and other inflammatory indications.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Retrieved on: 
Tuesday, April 23, 2024
FDA, Radiation, CMO, LLP, News, Advertising, Patient, Court, CKPT, BLA, CRL, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Checkpoint’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).